Page last updated: 2024-08-26

fulvestrant and ly 353381

fulvestrant has been researched along with ly 353381 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND	1
Chan, S	1
Christensen, GL; Freddie, CT; Lykkesfeldt, AE	1

Reviews

1 review(s) available for fulvestrant and ly 353381

Article	Year
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes	2002

Other Studies

2 other study(ies) available for fulvestrant and ly 353381

Article	Year
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12 Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen	2015
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene. Molecular and cellular endocrinology, 2004, May-31, Volume: 220, Issue:1-2 Topics: Breast Neoplasms; Cathepsin D; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Thiophenes; Transcription Factors	2004

Article

Year

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12

Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen

2015

A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.

Molecular and cellular endocrinology, 2004, May-31, Volume: 220, Issue:1-2

Topics: Breast Neoplasms; Cathepsin D; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Thiophenes; Transcription Factors

2004